Pharmaniaga's foray into Myanmar opens doors

KUALA LUMPUR: Pharmaniaga Bhd 's successful foray into Myanmar with its Sinovac Covid-19 vaccine bodes well for its strategy to expand its vaccine distribution business beyond the local sector.The pharmaceuticals group announced on Monday it had successfully exported the first batch of fill-finish Sinovac Covid-19 vaccines to Myanmar, manufactured by its wholly owned subsidiary Pharmaniaga Lifescience Sdn Bhd.Under its collaboration with Myanmar-based Hemas Mandalar Pharmaceuticals Ltd, Pharmaniaga will supply 200,000 doses of Sinovac vaccines in a few stages to two private hospitals in Yangon owned by Hemas Mandalar.In a Nov 16 note, MIDF Research reiterated a comment by Pharmaniaga group managing director Datuk Zulkarnain Md Eusope that the collaboration could fortify Pharmaniaga’s established international business relationships, and consequently develop future businesses in vaccine distribution. "The successful export had given Pharmaniaga ample assurance to explore similar opportunities in other countries in the Southeast Asia region, as well as in Africa. "The group is also awaiting regulatory permissions in other countries for the sale and distribution of Sinovac," it said.The research firm said Pharmaniaga's initiative to expand overseas was informed by the successful roll out of Malaysia's national immunisation programme.The programme is currently way ahead of schedule, with over 90% of the adult population and 70% of adolescents aged from 12 to 17 being fully vaccinated.Myanmar, in contrast, has one of the highest Covid-19 infection rates in the world and the lowest capacity for vaccinations with only 15% of its population being fully vaccinated. "We opine that, with the initiative taken by Pharmaniaga to distribute its fill-finish Sinovac vaccines beyond the local population, the number of vaccinated persons would increase, subsequently curbing infection rates in Southeast Asia faster than expected," said MIDF.However, it noted that the initiative and its success is subject to approval by authorities.MIDF has left its earnings forecast for Pharmaniaga unchanged as it believes the current collaboration with Myanmar has already been factored in the current quarter.Nevertheless, it is long-term positive on the group's prospects given its strategies in providing access to its pharmaceuticals and increasing their capacities and capabilities.It maintained its "buy" call with an unchanged target price of 98 sen.

Source:The Star

November 16, 2021 06:59 UTC


Maybank IB lifts AirAsia outlook on reopening of major markets

KUALA LUMPUR: While the Thai operations of AirAsia Group Bhd continues to drag on the earnings of the low-budget airline group, the falling rate of Covid-19 infections in the region offers optimism for a longer-term recovery, says Maybank Investment Bank Research.Thai AirAsia recently reported wider third-quarter losses of THB2.1bil resulting from a suspension of its flight operations to mitigate a third wave of the Covid-19 pandemic in the country.A "spectre of PN17 classification" looms over the Thai carrier, said Maybank IB, even as the Thai airline embarks on recapitalisation and restructuring initiatives.Consequently, Maybank IB forecasts that AirAsia may take a huge hit in the coming financial year. "For FY22E, our core net loss estimate is twice than before largely due to AAGB recognising the huge MYR1.1b in previously unrecognised losses from TAA," said Maybank IB.Over the longer-term, the research firm emphasised a swing in the group's net profit to the black in FY23, underpinned by the the decelerating rate of Covid-19 cases in the region.There has been a resumption of mass travel in all four of AirAsia's major markets, including Malaysia, which historically contributed 70% to 80% of group profits.Meanwhile, Maybank IB also noted that the Malaysian aviation industry is consolidating, which is positive for Malaysia AirAsia fares. "We forecast FY23E to swing to a core net profit of MYR255m from a core net loss of MYR439m before due to higher MAA fares. "With a profitable FY23E, we hope AAGB will no longer be classified as a PN17 listed issuer by then (if it is classified as such on 7 Jan 2022)," it said.Adding to the future prospects, Maybank IB said AirAsia may also list its digital assets, which will unlock a lot of value for the group.Given the improved outlook, the research firm upgraded AirAsia to "buy" from "sell" and raised its target price to RM1.36 from 36 sen previously.

Source:The Star

November 15, 2021 13:02 UTC


Tags
Finance      African Press Release      Lifestyle       Hiring       Health-care       Online test prep Corona       Crypto      Vpn      Taimienphi.vn      App Review      Company Review      Game Review      Travel      Technology     
  

Loading...

                           
/* -------------------------- overlay advertisemnt -------------------------- */